Investigational Drug Information for BLU-5937
✉ Email this page to a colleague
What is the development status for investigational drug BLU-5937?
BLU-5937 is an investigational drug.
There have been 10 clinical trials for BLU-5937.
The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2022.
The most common disease conditions in clinical trials are Cough, Pruritus, and Eczema. The leading clinical trial sponsors are Bellus Health Inc, Bellus Health Inc. - a GSK company, and [disabled in preview].
There are four US patents protecting this investigational drug and fifty-two international patents.
Summary for BLU-5937
| US Patents | 4 |
| International Patents | 52 |
| US Patent Applications | 33 |
| WIPO Patent Applications | 4 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2022-10-01) |
| Vendors | 15 |
Recent Clinical Trials for BLU-5937
| Title | Sponsor | Phase |
|---|---|---|
| Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant | Bellus Health Inc | Phase 1 |
| Assessment of the Pharmacokinetics of BLU-5937 Extended Release Formulation | Bellus Health Inc | Phase 1 |
| A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough | Bellus Health Inc | Phase 3 |
Clinical Trial Summary for BLU-5937
Top disease conditions for BLU-5937
Top clinical trial sponsors for BLU-5937
US Patents for BLU-5937
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| BLU-5937 | ⤷ Sign Up | Selective P2X3 modulators | BELLUS HEALTH COUGH INC. (Laval, Quebec, CA) NEOMED INSTITUTE (Montreal, Quebec, CA) | ⤷ Sign Up |
| BLU-5937 | ⤷ Sign Up | Imidazopyridine compounds and uses thereof | Neomed Institute (Montreal, Quebec, CA) | ⤷ Sign Up |
| BLU-5937 | ⤷ Sign Up | Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents | NeRRe Therapeutics Limited (Herts, GB) | ⤷ Sign Up |
| BLU-5937 | ⤷ Sign Up | Imidazopyridine compounds and uses thereof | ⤷ Sign Up | |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for BLU-5937
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| BLU-5937 | Australia | AU2018342751 | 2037-09-18 | ⤷ Sign Up |
| BLU-5937 | Canada | CA3076150 | 2037-09-18 | ⤷ Sign Up |
| BLU-5937 | China | CN111601601 | 2037-09-18 | ⤷ Sign Up |
| BLU-5937 | European Patent Office | EP3684368 | 2037-09-18 | ⤷ Sign Up |
| BLU-5937 | Israel | IL273348 | 2037-09-18 | ⤷ Sign Up |
| BLU-5937 | Japan | JP2020534355 | 2037-09-18 | ⤷ Sign Up |
| BLU-5937 | South Korea | KR20200092938 | 2037-09-18 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
